Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats

Xing, Chuan; Lv, Bo; Zhao, Han; Wang, Dongxu; Li, Xuesong; He, Bing

doi:10.1016/j.jsbmb.2021.105992

Cited by 14 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xing et al 51 24 SD female rats were randomly divided into PCOS with IR group (n = 18) and the control group (n = 6). The SD rats in the PCOS with IR model were randomly divided into 3 arm groups: MET (n = 6), EXE (n = 6), and PCOS with IR (n = 6) that were treated with letrozole for a total of 3 weeks.…”

Section: Study Design Main Resultsmentioning

confidence: 99%

“…Significant reductions in body weight, abdominal fat deposition, fasting insulin levels, fasting glucose levels, and IR markers were observed when EXE was administered in preclinical PCOS models. [49][50][51] The upregulation of the molecular pathway of the AMP-activated protein kinase α-SIRT1 was also demonstrated after EXE therapy; the downregulation of this molecular pathway was associated with higher IR during a PCOS state. 49 The possible activity of EXE on reproductive dysfunction and ovarian morphology was investigated in 2 studies.…”

Section: Exenatide Preclinical Evidencementioning

confidence: 97%

“…49 The possible activity of EXE on reproductive dysfunction and ovarian morphology was investigated in 2 studies. 50,51 In the first study, 45 female SD rats were randomly divided into 2 arms: the DHEA arm (n = 35) and the control arm (n = 10). 50 The DHEA group was then subdivided into 3 groups: the EXE arm (n = 10), the MET arm (n = 10) and the DHEA arm (n = 15), in which the rats were treated with saline for a total of 4 weeks.…”

Section: Exenatide Preclinical Evidencementioning

confidence: 99%

“…In the second randomized study, 24 female SD rats were separated into the PCOS with IR arm group (n = 18) and the control group (n = 6). 51 The SD rats in the PCOS with IR model were randomized into 3 arms: MET (n = 6), EXE (n = 6) and PCOS with IR (n = 6) that were treated with letrozole for 3 weeks. Interestingly, 83.3% of the rats in the EXE arm and 67.7% of the rats in the MET arm recovered their regular estrous cycles, while the PCOS with IR rats experienced irregular estrous cycles.…”

Section: Exenatide Preclinical Evidencementioning

confidence: 99%

See 3 more Smart Citations

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

Papaetis¹,

Kyriacou²

2022

Adv Clin Exp Med

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a disorder that involves several organ systems and cellular pathways. It is strongly influenced by environmental and epigenetic factors. The principal goal of all therapeutic approaches to individuals with reproductive abnormalities is the treatment of subfertility or the regulation of menstruation when pregnancy is not desired. Obesity is closely related to insulin resistance (IR) and subsequent hyperinsulinemia, which aggravate hyperandrogenism and impair early follicle development. Weight loss is of vital importance for overweight/obese individuals with anovulatory infertility. The GLP-1R agonists have achieved remarkable weight reduction and abdominal fat loss in patients with type 2 diabetes (T2D), as well as in overweight/obese individuals and individuals with prediabetes. They have also been shown to promote lower fasting insulin levels and insulin resistance markers. These beneficial effects have been suggested to be particularly helpful in women with PCOS, while their possible role in the hypothalamic-pituitary-gonadal axis is under intense research. This review analyzes the current evidence for GLP-1R agonists, focusing on their effects on ovarian morphology, menstrual dysfunction and fertility outcomes. It also discusses their future role in achieving targeted therapeutic approaches.

show abstract

Section: Study Design Main Resultsmentioning

confidence: 99%

Section: Exenatide Preclinical Evidencementioning

confidence: 97%

Section: Exenatide Preclinical Evidencementioning

confidence: 99%

Section: Exenatide Preclinical Evidencementioning

confidence: 99%

See 2 more Smart Citations

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

Papaetis¹,

Kyriacou²

2022

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Interestingly, our results also emphasized that compared with MET, exenatide can have stronger effects on regulating the PI3K/AKT pathway, reducing liver TG deposition, and upregulating the expression levels of SHBG and HNF-4α in the liver tissue of PCOS-with-IR rats. 93 Although GLP-1RA and DPP-4 inhibitors have promising therapeutic effects, more extensive clinical trials are needed to determine the role and mechanism of action of incretin-based therapies in improving SHBG levels and managing PCOS.…”

Section: Glucagon-like Peptide-1 Receptor Agonists (Glp-1 Ras)mentioning

confidence: 99%

Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment

Xing¹,

Zhang²,

Zhao³

et al. 2022

IJWH

Self Cite

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases causing infertility in women of childbearing age. It is characterized by hyperandrogenemia (HA), chronic anovulation, and polycystic ovary morphology (PCOM). Most women with PCOS have metabolic abnormalities. Sex hormone-binding globulin (SHBG), a transport carrier that binds estrogen and androgens and regulates their biological activity, is usually used as an indicator of hyperandrogenism in women with PCOS. Low serum SHBG levels are considered a biomarker of metabolic abnormalities and are associated with insulin resistance (IR), HA, and abnormal glucose and lipid metabolism in PCOS patients. SHBG is also related to the long-term prognosis of PCOS, whereas SHBG gene polymorphism is associated with PCOS risk. In addition, the administration of metformin (MET), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), thiazolidinediones (TZDs), compound oral contraceptives (COCs), as well as nutrient supplements such as inositol (MI), vitamin D, and synbiotics can regulate SHBG levels to ameliorate PCOS complications and improve prognosis. This review focuses on the interaction between SHBG and various PCOS complications as well as the regulation of SHBG by various drugs and nutrients and its therapeutic effects on PCOS.

show abstract

Polycystic ovary syndrome: Current scenario and future insights

Kulkarni,

Gupta,

Ratre

et al. 2023

Drug Discovery Today

View full text Add to dashboard Cite

Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats

Cited by 14 publications

References 32 publications

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment

Polycystic ovary syndrome: Current scenario and future insights

Contact Info

Product

Resources

About